New Targets and Treatments for Follicular Lymphoma. Disclosures

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "New Targets and Treatments for Follicular Lymphoma. Disclosures"

Transcription

1 Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from: Pharmacyclics, and Seattle Genetics Contracted Research from: Bristol Myers Squibb, and Janssen Pharmaceuticals, Inc. 1

2 Intro/Outline Follicular lymphoma, presentation and indications for treatment Review of induction therapy options for advanced disease Evidence for maintenance therapy Novel therapies and investigational agents for relapsed follicular lymphoma Clinical Presentation Often asymptomatic Slowly progressive adenopathy Incidental findings Patients are often not sick 2

3 Criteria for Treatment (GELF) Involvement of 3 sites, each measuring 3 cm Any nodal or extranodal tumor mass with a diameter of 7 cm B symptoms Splenomegaly Pleural effusions or peritoneal ascites Cytopenias Leukemic presentation FLIPI Characteristic RR (Death) Age > 60 years 2.38 Stage III-IV 2.00 Hgb < 12.0g.dL 1.55 Elevated LDH 1.50 Nodal sites > Solal Céligny, et al. Blood. 2004;104:

4 FLIPI and OS Risk Group No. of Risk 5-year OS, % 10-Year OS, % Factors Low Intermediate High Roughly half of all patients with FLIPI 3 or higher die within 5 years Original FLIPI score developed in the pre-rituximab era Solal Céligny, et al. Blood. 2004;104: FLIPI: Survival Probability Solal Céligny, et al. Blood. 2004;104:

5 Induction Therapy: B R vs R CHOP Pts with previously untreated Stage III or IV NHL of the following types: Follicular Waldenström Marginal zone Small lymphocytic Mantle cell Age 18 years WHO PS 0-2 R Bendamustine-rituximab CHOP-rituximab Bendamustine 90 mg/m 2 Day 1, 2 + R Day 1, max 6 cycles, every 4 weeks. CHOP-R, max 6 cycles, every 3 weeks. Rummel MJ, et al. Blood. 2009;114: Abstract 405. B-R vs CHOP-R: PFS Rummel MJ, et al. Lancet Oncol

6 B R vs R CHOP/R CVP BRIGHT study (Flinn et al, Blood 2013) Patients randomized to B R or R CHOP/R CVP (each site assigned one of the standard therapies) Non inferiority study B R non inferior to both R CHOP and R CVP with respect to CR rate. Non hematologic toxicity improved with B R. B R + Bortezomib Novel Approaches Current ECOG study in comparison to B R. Overall Response Rate is 88% in relapsed FL R Lenalidomide CALGB Phase II Study Rituximab x 4, then cycles 4, 6, 8 and 10 Lenalidomide 20mg daily days 1 21 of a 28 day cycle x 12 Overall Response Rate: 93% 2 year PFS 89% Fowler et al, J Clin Oncol 2011; Martin et al, ASCO Abstracts

7 Conclusions Induction Therapy Bendamustine Rituximab appropriate in most cases Studies underway to both intensify and lessen therapy Expect therapy to become more tailored based on individual risk factors Registration High tumor burden untreated follicular lymphoma Rituximab Maintenance PRIMA: Study Design INDUCTION Immunochemotherapy 8 x Rituximab + 8 x CVP or 6 x CHOP or 6 x FCM Primary endpoint: Progression free survival (PFS) from randomization (to rituximab maintenance or observation) CR/Cru PR PD/SD off study Secondary endpoints Event free survival (EFS), overall survival (OS) Time to next anti lymphoma treatment (TTNLT), time to next chemotherapy (TTNCT) Response rates at end of maintenance Safety and toxicity Quality of life (QoL) (FACT G and EORTC scales) *Stratified by response after induction, regimen of chemo, and geographic region Frequency of clinical, biological and CT-scan assessments identical in both arms Five additional years of follow-up MAINTENANCE Rituximab maintenance 375 mg/m 2 every 8 weeks for 2 years Random 1:1* Observation Salles GA, et al. J Clin Oncol. 2010;28(7s): Abstract

8 Patient disposition Induction Maintenance Patients evaluable (N = 1202)* R-CHOP N = 885 Randomized N = 769 Patients registered: N = 1217 R-CVP N = 272 Randomized N = 222 Patients randomized: N = 1018 R-FCM N = 45 Randomized N = 28 * 15 pts in 3 sites closed prematurely 9 pts did not receive chemo 147 pts withdrew during or at the end of induction (failure to respond; toxicity) 28 pts failed to be randomized 1 pt died during the randomization process Observation N = 513 Rituximab N = 505 PRIMA PFS OUTCOME 3 year PFS: 79% (R Maint) 57.6% (Obs) Salles G, Lancet

9 PRIMA OS No significant OS benefit E4402 (RESORT) Pts with low tumor burden treated with R x 4 followed by maintenance vs retreatment at progression. Time to Treatment Failure Time to Chemotherapy Kahl et al, ASH

10 Maintenance Rituximab Summary Likely a PFS benefit and opportunity to delay next therapy Unclear role after B R (E2408 may help answer this) No evidence of OS benefit Should be discussed individually with each patient Relapsed/Refractory FL B cell receptor signaling pathway Woyach et al, Blood

11 Ibrutinib BTK inhibitor Phase I Study of Ibrutinib MTD not reached; standard dose is 560mg ORR 54.5%, median duration of response 12.3 months Ongoing multisite study just completed enrollment Fowler et al, ASH 2012 Idelalisib PI3Kδ inhibitor Phase 2 Study of Idelalisib Dose 150mg twice daily Response rate 57%, median duration 12.5 months Toxicities: Neutropenia LFT abnormalities Diarrhea Pneumonia Gopal et al, NEJM

12 Ofatumumab: CD20 Antibodies ORR 10 13% Median PFS: 5.8 months Czuczman et al, Blood 2012 CD20 Antibodies GA101 Obinutuzumab Phase II study in rel/ref follicular lymphoma ORR 55% at recommended dose Median PFS 11.9 months Salles G, et al. J Clin Oncol

13 BCL2 Inhibitor ABT199 Oral agent active in several subtypes of NHL Responses seen in 2/7 patients with follicular lymphoma in Phase I Study. Toxicities: Tumor lysis syndrome Cytopenias Febrile Neutropenia Davids et al, ASCO Abstracts 2013 Agents Under Investigation at Emory ABT 199 Nivolumab (PD1 inhibitor) Buparlisib (Pan selective PI3K inhibitor) Alisertib (Aurora Kinase inhibitor) 13

14 Other Treatments for Rel/Ref FL Chemo immunotherapy B R R CVP/R CHOP Fludarabine Salvage NHL regimens Radioimmunotherapy Lenalidomide Autologous/Allogeneic Transplants Conclusions Several options that are better than R CHOP for induction therapy Consider maintenance rituximab in all cases, but with no clear OS benefit Numerous options for relapsed/refractory FL Strongly consider enrollment on clinical trial For fit/motivated patients, transplant can be considered 14

Update on Follicular Lymphoma. Brad Kahl, M.D.

Update on Follicular Lymphoma. Brad Kahl, M.D. Update on Follicular Lymphoma Brad Kahl, M.D. Follicular Lymphoma: 25% of NHL Cases Other subtypes (9%) T and NK cell (12%) Burkitt (2.5%) Diffuse large B cell (DLBCL) (30%) Mantle cell (6%) Follicular

More information

Rituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy

Rituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy Rituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy G. A. Salles, J. F. Seymour, P. Feugier, F. Offner, A. Lopez-Guillermo,

More information

Histopathologic results

Histopathologic results Self evaluation 1 Clinical Case 55-year-old woman Bilateral enlargement of cervical, axillary and inguinal lymph nodes, largest diameter > 6 cm Hepatosplenomegaly. Enlargement of retroperitoneal, mesenteric

More information

Frequency of NHL Subtypes in Adults

Frequency of NHL Subtypes in Adults Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults

More information

Audience Response Question?

Audience Response Question? Presenter Disclosure Information Session 4: 3:30 PM - 4:15 PM Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman, MD The following relationships

More information

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular

More information

6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic

6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic Follicular and Other Slow Growing Lymphomas Stephen Ansell, MD, PhD Mayo Clinic 1 Learning Objectives Start with an overview of Follicular and other slow growing lymphomas Discuss current and emerging

More information

Audience Response Question? Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management. Presenter Disclosure Information

Audience Response Question? Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management. Presenter Disclosure Information Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM Miami, FL December 18, 2009 Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman,

More information

Mantle Cell Lymphoma Understanding Your Treatment Options

Mantle Cell Lymphoma Understanding Your Treatment Options New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department

More information

David Loew, LCL MabThera

David Loew, LCL MabThera MabThera The star continues to rise David Loew, LCL MabThera MabThera the star continues to raise Group sales (CHF bn) 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 2001 2002 2003 2004 2005 Outstanding clinical

More information

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade

More information

The role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D.

The role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D. The role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D. Oncology Institute of Southern Switzerland (IOSI) Swiss Group for Clinical Cancer Research (SAKK) WHO grading of follicular lymphoma

More information

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line

More information

Rituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008

Rituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008 Rituximab in Non - Hodgkins Lymphoma Fatima Bassa, Dept. of Haematology October 2008 World Health Organization lymphoma classification (2001) Peripheral B-cell neoplasms: B-chronic lymphocytic leukemia/small

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies

More information

Follicular Lymphoma. Aruna K. Reddy, MD. Hematology& Oncology Peace Health Southwest Medical Center

Follicular Lymphoma. Aruna K. Reddy, MD. Hematology& Oncology Peace Health Southwest Medical Center Follicular Lymphoma Aruna K. Reddy, MD Hematology& Oncology Peace Health Southwest Medical Center Follicular Lymphoma Malignant neoplasm resulting from clonal proliferation of malignant B-cells Second

More information

Réda Bouabdallah, MD Institut Paoli-Calmettes, Marseille, France. Oran, May, 8th, 2010

Réda Bouabdallah, MD Institut Paoli-Calmettes, Marseille, France. Oran, May, 8th, 2010 FIRST LINE TREATMENT IN FOLLICULAR LYMPHOMA Current Status Réda Bouabdallah, MD Institut Paoli-Calmettes, Marseille, France Oran, May, 8th, 2010 FL is a complex disease One disease, but many profiles 20%

More information

Guidelines for the Management of Follicular Lymphoma

Guidelines for the Management of Follicular Lymphoma Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World

More information

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,

More information

Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics

Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use

More information

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory

More information

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN + IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start

More information

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引 前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金

More information

Non-Hodgkin Lymphoma Luciano J. Costa MD, PhD

Non-Hodgkin Lymphoma Luciano J. Costa MD, PhD Non-Hodgkin Lymphoma Luciano J. Costa MD, PhD Assistant Professor Department of Medicine Division of Hematology and Oncology Medical University of South Carolina Objectives Discuss the molecular basis

More information

Anti-HCV therapy in HCV-related NHL

Anti-HCV therapy in HCV-related NHL Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral

More information

1. Introduction. 2. Clinical aspects

1. Introduction. 2. Clinical aspects 1. Introduction MabThera (rituximab) is a genetically engineered chimeric mouse/human monoclonal antibody which binds specifically to the transmembrane antigen, CD20. This antigen is located on pre-b-

More information

ICML CLL: Therapie des Rezidivs

ICML CLL: Therapie des Rezidivs ICML CLL: Therapie des Rezidivs Thomas Elter Universitätsklinikum Köln Deutsche CLL Studiengruppe 14.09.2013 Hamburg LUGANO: WAS GIBT ES ZUR CLL IN DER 2. LINIE? Publikationen zur CLL insgesamt: 55 Diagnostik

More information

Cure versus control: Which is the best strategy?

Cure versus control: Which is the best strategy? Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control

More information

Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need

Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need Hagop M. Kantarjian, MD Chairman, Leukemia Department Department of Hematology

More information

bnmqwertyuiopasdfghjklzxcvbn mqwertyuiopasdfghjklzxcvbnm qwertyuiopasdfghjklzxcvbnmq ertyuiopasdfghjklzxcvbnmqwer tyuiopasdfghjklzxcvbnmqwerty

bnmqwertyuiopasdfghjklzxcvbn mqwertyuiopasdfghjklzxcvbnm qwertyuiopasdfghjklzxcvbnmq ertyuiopasdfghjklzxcvbnmqwer tyuiopasdfghjklzxcvbnmqwerty bnmqwertyuiopasdfghjklzxcvbn mqwertyuiopasdfghjklzxcvbnm qwertyuiopasdfghjklzxcvbnmq wertyuiopasdfghjklzxcvbnmqw ertyuiopasdfghjklzxcvbnmqwer Follicular Lymphoma Overview tyuiopasdfghjklzxcvbnmqwerty Lymphoma

More information

CHRONIC LYMPHOCYTIC LEUKEMIA

CHRONIC LYMPHOCYTIC LEUKEMIA CHRONIC LYMPHOCYTIC LEUKEMIA Executive Summary Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the Western world, but is significantly less frequent in Asia. The median age of

More information

Non Hodgkins Lymphoma primary treatment

Non Hodgkins Lymphoma primary treatment Non Hodgkins Lymphoma primary treatment R-CHOP 21 R-CHOP 14 Primary chemotherapy for diffuse large B cell NHL. Treatment option for: * low-grade NHL with high-grade transformation or high risk features.

More information

Effective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm

Effective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Effective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Uses of Monoclonal Antibodies for the Treatment of Non-Hodgkin

More information

East Midlands Cancer Network Guidelines for the Management of Follicular NHL

East Midlands Cancer Network Guidelines for the Management of Follicular NHL East Midlands Cancer Network Guidelines for the Management of Follicular NHL Written by: Dr Matthew Lyttelton, Professor Martin Dyer, Dr Andrew Haynes Consultation Group: EMCN Haematology NSSG Summary

More information

STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous

More information

Indolent Lymphomas. Dr Ram Malladi

Indolent Lymphomas. Dr Ram Malladi Indolent Lymphomas Dr Ram Malladi Follicular lymphoma is commonest indolent lymphoma INDOLENT LYMPHOMA % of all NHL Follicular Lymphoma 22 Small lymphocytic lymphoma 6 Marginal zone lymphoma 6 Lymphoplasmacytic

More information

U.S. Food and Drug Administration

U.S. Food and Drug Administration U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained

More information

Treatment results with Bortezomib in multiple myeloma

Treatment results with Bortezomib in multiple myeloma Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of

More information

Management of low grade glioma s: update on recent trials

Management of low grade glioma s: update on recent trials Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,

More information

EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com

EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com Investor Relations: Stan Panasewicz Phone: +1 732-524-2524 Louise Mehrotra Phone:

More information

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from

More information

Characteristics and Prognosis of Patients with Richter s Transformation of Chronic Lymphocytic Leukemia: Experience with FDG/PET

Characteristics and Prognosis of Patients with Richter s Transformation of Chronic Lymphocytic Leukemia: Experience with FDG/PET Characteristics and Prognosis of Patients with Richter s Transformation of Chronic Lymphocytic Leukemia: Experience with FDG/PET Lorenzo Falchi, Long Trinh, Edith M Marom, Mylene Truong, Ellen J Schlette,

More information

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype? Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in

More information

In the last decade, passive immunotherapy

In the last decade, passive immunotherapy Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Immunotherapy with Rituximab in Follicular Lymphomas Carmen SAGUNA, MD a ; Ileana Delia MUT, MD, PhD a ; Anca Roxana LUPU, MD, PhD a ; Mihaela TEVET,

More information

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need?

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,

More information

Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma

Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University

More information

Indolent Lymphomas. American Academy of Insurance Medicine 121 st Annual Meeting. Hilton LaJolla October 2012

Indolent Lymphomas. American Academy of Insurance Medicine 121 st Annual Meeting. Hilton LaJolla October 2012 Indolent Lymphomas American Academy of Insurance Medicine 121 st Annual Meeting Hilton LaJolla October 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC,

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010) MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.

More information

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate + Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN

More information

CHRONIC LYMPHOCYTIC LEUKEMIA

CHRONIC LYMPHOCYTIC LEUKEMIA CHRONIC LYMPHOCYTIC LEUKEMIA Farrukh Awan, MD Associate Professor of Medicine Division of Hematology The Ohio State University Jun 2015 cll.osu.edu Definition of CLL IWCLL - 2008 Small, clones of mature

More information

Trials in Elderly Melanoma Patients (with a focus on immunotherapy)

Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP

More information

Rituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma

Rituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma Issue date: June 2011 Rituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma This guidance was developed using the the single technology appraisal process NICE technology

More information

Treatment of low-grade non-hodgkin lymphoma

Treatment of low-grade non-hodgkin lymphoma Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade

More information

Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,

More information

The role of PET-CT in Follicular Lymphoma Prognostic and Predictive

The role of PET-CT in Follicular Lymphoma Prognostic and Predictive The role of PET-CT in Follicular Lymphoma Prognostic and Predictive Judith Trotman University Sydney Massimo Federico University Modena Menton 2012 How we used to look at FL 1. Indolent B-cell lymphoma

More information

Multiple Myeloma: Novel Agents. Robert A. Kyle, M.D. Germany June 28, 2008. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida

Multiple Myeloma: Novel Agents. Robert A. Kyle, M.D. Germany June 28, 2008. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Multiple Myeloma: Novel Agents Robert A. Kyle, M.D. Germany June 28, 2008 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Multiple Myeloma Untreated Initial Therapy Transplant eligible Multiple

More information

CAR T cell therapy for lymphomas

CAR T cell therapy for lymphomas CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What

More information

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable

More information

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-hodgkin s lymphoma

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-hodgkin s lymphoma DOI: 10.3310/hta13suppl2/06 Health Technology Assessment 2009; Vol. 13: Suppl. 2 Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-hodgkin s lymphoma A Boland, A Bagust,

More information

Outline of thesis and future perspectives.

Outline of thesis and future perspectives. Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

cancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146

cancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146 Hematopoietic Stem Cell Transplant in HIV- related lymphoma Song Zhao, MD PhD Hematology-Oncology Program University of Washington/FHCRC Underlying Causes of Death in HIV-infected Adults 2000 2005 cancer

More information

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007

More information

NATIONAL CANCER DRUG FUND PRIORITISATION SCORES

NATIONAL CANCER DRUG FUND PRIORITISATION SCORES NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated

More information

Acute Myeloid Leukemia

Acute Myeloid Leukemia Acute Myeloid Leukemia Upfront Therapy in Newly Diagnosed Elderly AML Patients: Is Decitabine (DAC) the new standard? Raoul Tibes, MD, PhD Senior Associate Consultant, Mayo Clinic Arizona Associate Director,

More information

Rituximab in the Management of Follicular Lymphoma

Rituximab in the Management of Follicular Lymphoma Hong Kong J Radiol. 2011;14(Suppl):S63-7 REVIEW ARTICLE Rituximab in the Management of Follicular Lymphoma YL Kwong Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong

More information

Lymphoma Diagnosis and Classification

Lymphoma Diagnosis and Classification Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various

More information

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Aggressive lymphomas. Michael Crump Princess Margaret Hospital Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:

More information

rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited

rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited 06 June 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Aggressive Lymphomas in the Elderly SIOG Berlin Oct 09 Lorenz Trümper Universitätsmedizin Göttingen

Aggressive Lymphomas in the Elderly SIOG Berlin Oct 09 Lorenz Trümper Universitätsmedizin Göttingen Treatment of aggressive B-Cell Lymphomas in the Elderly Lorenz Trümper Abteilung Hämatologie & Onkologie Göttingen Comprehensive Cancer Center Universitätsmedizin Göttingen Aggressive Lymphomas in the

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

Lymphomes folliculaires: questions actuelles et perspectives

Lymphomes folliculaires: questions actuelles et perspectives Lymphomes folliculaires: questions actuelles et perspectives Hervé Tilly herve.tilly@chb.unicancer.fr Centre Henri-Becquerel Rouen, France Université de Rouen Rouen, France The Lymphoma Study Association

More information

Chemoimmunotherapy resistant follicular lymphoma A single institutional study

Chemoimmunotherapy resistant follicular lymphoma A single institutional study Cancer Research Journal 2014; 2(5): 93-97 Published online September 30, 2014 (http://www.sciencepublishinggroup.com/j/crj) doi: 10.11648/j.crj.20140205.13 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online)

More information

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black

More information

the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009

the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy

More information

Treatment of follicular lymphoma

Treatment of follicular lymphoma Treatment of follicular lymphoma Mathias J. Rummel Med. Klinik IV/ V - Hämatologie Klinikum der Justus-Liebig Liebig-Universität Gießen MJR Therapy of Follicular Lymphoma wait and see policy alkylating

More information

What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center

What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.

More information

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012 Overview of Ovarian Cancer Dr. Sinead Noonan 13/03/2012 Ovarian Cancer 4 th most common cause of cancer death in women 15,000 deaths/year in the US Each year 300 new cases in Ireland 80% epithelial cell

More information

Pre-HCT Treatment for Hodgkin s / Non-Hodgkin s Lymphoma

Pre-HCT Treatment for Hodgkin s / Non-Hodgkin s Lymphoma Pre-HCT Treatment for Hodgkin s / Non-Hodgkin s Lymphoma This appendix is intended to provide additional information on: Common pre-hct treatments for lymphoma, Lines of therapy, Cycles, and How to report

More information

Endpoint Selection in Phase II Oncology trials

Endpoint Selection in Phase II Oncology trials Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill aivanova@bios.unc.edu Primary endpoints in Phase II trials Recently looked at journal articles

More information

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage

More information

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,

More information

Bendamustine for the fourth-line treatment of multiple myeloma

Bendamustine for the fourth-line treatment of multiple myeloma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard

More information

Perspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data

Perspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data Perspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data Summary Article James O. Armitage, MD Presented through a strategic collaboration by A series of 5 expert interviews were conducted, focusing on

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib

More information

Latest developments in management. Gianfilippo Bertelli Consultant Medical Oncologist Swansea

Latest developments in management. Gianfilippo Bertelli Consultant Medical Oncologist Swansea Latest developments in management Gianfilippo Bertelli Consultant Medical Oncologist Swansea Optimizing management of ovarian cancer in South Wales Diagnosis and referral pathways: Role of GPs, gynaecologists,

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information

Epithelial Ovarian Cancer

Epithelial Ovarian Cancer Epithelial Ovarian Cancer Fred Ueland, MD University of Kentucky Gynecologic Oncology Epithelial Ovarian Cancer Radiotherapy Ovarian Cancer Radiotherapy Ovarian cancer is usually radiosensitive Whole abdominal

More information

A Study To Evaluate PF With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Study To Evaluate PF With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome A service of the U.S. National Institutes of Health Trial record 1 of 5 for: efficacy of PF-04449913 Previous Study Return to List Next Study A Study To Evaluate PF-04449913 With Chemotherapy In Patients

More information

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Update in Hematology Oncology Targeted Therapies. Mark Holguin Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning

More information

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4 Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.

More information

PERSPECTIVES ON THE TREATMENT OF MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA IN 2015 AND BEYOND

PERSPECTIVES ON THE TREATMENT OF MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA IN 2015 AND BEYOND PERSPECTIVES ON THE TREATMENT OF MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA IN 2015 AND BEYOND Summary of presentations from the Celgene satellite symposium, held at the 20 th Congress of the European

More information

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy

More information

PROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.

PROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic

More information

Follicular Lymphoma: Current Management and Future Directions

Follicular Lymphoma: Current Management and Future Directions Treatment decisions and outcomes for patients with follicular lymphoma may be improved with newer diagnostic tests and novel targeted agents. George Van Hook. Barns in Summer. Oil on linen, 22 28. Follicular

More information

Follicular lymphoma. What is follicular lymphoma? Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.

Follicular lymphoma. What is follicular lymphoma? Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org. Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.uk is a cancer of the lymphatic system, a type of non-hodgkin lymphoma. Even though more than 12,000 people are diagnosed

More information

Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre

Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Background Non-Hodgkin s lymphoma (NHL) makes up approximately 85% of all lymphomas. They are a heterogeneous collection

More information

Waldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP

Waldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP Waldenström Macroglobulinemia: The Burning Questions IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP Are my kids going to get this? Familial seen in approximately 5 10% of all CLL patients and can be associated

More information